Marketed products

Solaraze®

Solaraze®

(diclofenac sodium 3%)

Solaraze was developed by Skyepharma using its proprietary technologies.

  • Primary indicationactinic keratoses
  • PartnersSandoz (US) and Almirall (EU)
  • Descriptiona nonsteroidal anti-inflammatory drug (NSAID) treating actinic keratosis, a precancerous skin growth usually caused by sun exposure.

EXPAREL® (US)

EXPAREL® (US)

(bupivacaine liposome injectable suspension)

Exparel, was initially developed by Skyepharma and the development was completed by Pacira Pharmaceuticals following the sale of Skyepharma’s injectable business.

  • Primary indicationadmininistration into the surgical site to produce post-surgical analgesia
  • PartnerPacira Pharmaceuticals
  • DescriptionInjectable product for single-dose administration into the surgical site to produce post-surgical analgesia.